Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, presented results from two small single-center clinical studies examining skin quality changes in individuals taking medical weight loss (MWL) medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a company press release.

The studies were presented at the Science of Skin Summit in Austin, Texas, running Sept. 17-20, 2026. One study evaluated a 12-week targeted skincare regimen alone, while the second evaluated a six-week combination of the skincare regimen with DiamondGlow dermabrasion treatments. The skincare regimen included a growth factor serum, a neck cream, and a firming and toning body lotion.

The 12-week skincare study included nine participants who completed the study. Investigators reported statistically significant improvements in measures including dryness, skin tone evenness, crepiness, tactile roughness, lines and wrinkles, and skin texture, with changes observed as early as week two. Participants reported that facial skin appeared approximately 10 years younger after four weeks of twice-daily growth factor serum use.

The six-week DiamondGlow plus skincare study included 11 participants who completed at least one post-treatment assessment. Skin quality improvements were observed immediately after treatment, and participants reported facial skin appeared approximately 7.5 years younger after three DiamondGlow treatments combined with six weeks of the skincare regimen.

"These early data contribute clinical evidence evaluating targeted skincare and noninvasive dermabrasion approaches in individuals taking medical weight loss medications," said Elizabeth Makino, director of clinical development and global scientific affairs for skincare research and development at Allergan Aesthetics. "Additional research in larger populations will help further characterize these findings."

Both studies covered treatment areas including the face, neck, upper inner arms, and distal thighs. The company noted that results varied by regimen, treatment area, time point, and sample size.